Clinical trials · District of Columbia
Pediatric ALL clinical trials in District of Columbia
We’re tracking 63 recruiting pediatric all studies with a site in District of Columbia — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in District of Columbia
- NCT03827694Recruiting
Testing a noninvasive scan for serious lung mold infections in kids
This study uses noninvasive breathing/relates imaging (MRI or CT) to help diagnose mold infections in the lungs in children and young adults. It may help doctors find these infections sooner, especially in people with weakened immune systems.
Washington D.C., District of ColumbiaAges 4 months–21 years - NCT05948943RecruitingPhase 2/Phase 3
Alpelisib for lymphatic malformations with a PIK3CA change
This trial tests alpelisib (a targeted medicine) for people who have lymphatic malformations (LyM) that cause symptoms and have a PIK3CA mutation. It may help shrink or control these lesions when other procedures are delayed until after the first 24 weeks.
Washington D.C., District of ColumbiaAges birth–100 years - NCT04485559RecruitingPhase 1
Testing two drugs for kids and young adults with recurrent gliomas
This trial is testing a combination of two oral drugs, trametinib and everolimus, to see if they can help children and young adults whose glioma (a type of brain tumor) has come back or is growing despite previous treatment. It includes both low-grade and high-grade gliomas, and aims to stop the tumor from growing.
Washington D.C., District of ColumbiaAges 1–25 - NCT04573140RecruitingPhase 1
RNA vaccine study for newly diagnosed adult and pediatric brain tumors
This Phase 1 trial studies an “RNA-lipid particle” vaccine given after surgery for certain newly diagnosed brain cancers (glioblastoma in adults, high-grade glioma in children/teens). The goal is to see whether the vaccine is safe and can train the immune system to fight the tumor.
Washington D.C., District of ColumbiaAges 4 years+ - NCT04649242RecruitingPhase 3
Migraine pain relief study for kids and teens
This trial studies a medicine for stopping a migraine attack in children and teens. It may help families understand which treatment works best during acute (during-attack) migraine pain.
Washington D.C., District of ColumbiaAges 6–17 - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Washington D.C., District of ColumbiaAges Up to 22 years - NCT06796543Recruiting
Radiation for young patients with sarcoma that has spread
This trial tests whether targeted radiation can help children and young adults with sarcoma that has spread to a few spots in the body. It's for those who are newly diagnosed (Stratum A) or whose sarcoma has come back or worsened (Stratum B).
Washington D.C., District of ColumbiaAges Up to 39 years - NCT05040178Recruiting
Study of Carbaglu® use for MMA and PA
This observational study looks at how Carbaglu® is used and how well it works for people with methylmalonic acidemia (MMA) or propionic acidemia (PA). It may help doctors understand real-world care for adults and children living with these conditions.
Washington D.C., District of ColumbiaAges Any age - NCT05076175RecruitingPhase 2/Phase 3
Oral ozanimod for children with moderate to severe ulcerative colitis
This trial tests whether an oral medicine called ozanimod can improve ulcerative colitis (UC) in children whose disease is moderate to severe. It’s meant for kids who didn’t fully respond—or couldn’t tolerate—standard UC treatments.
Washington D.C., District of ColumbiaAges 2–17 - NCT05096481RecruitingPhase 2
Vaccine trial for children with certain brain tumors
This Phase 2 study tests a vaccine made to target CMV (a virus) in order to treat children with medulloblastoma or newly diagnosed high-grade glioma/DIPG. If you’re eligible, you’d receive the study vaccine and the team would closely watch how well it’s tolerated and how your cancer responds.
Washington D.C., District of ColumbiaAges 3–39 - NCT05121324RecruitingPhase 3
Tested higher-dose seizure medicine for children during EMS care
This trial studies the best dose of a seizure medicine for children who are actively seizing while emergency medical teams are treating them. It may help EMS crews give safer, more effective treatment during transport.
Washington D.C., District of ColumbiaAges 6 months–13 years - NCT05135975RecruitingPhase 2
Cabozantinib maintenance to help stop pediatric cancer from growing
This trial studies cabozantinib given after standard treatment to try to keep high-risk pediatric solid tumors from coming back or getting worse. It is offered to children and young adults whose cancer has not fully disappeared but is not progressing at the start of this maintenance phase.
Washington D.C., District of ColumbiaAges 1.5 years–40 years - NCT05233397RecruitingPhase 2
Actemra for children and young adults with craniopharyngioma
This trial studies Actemra (tocilizumab) to slow or shrink adamantinomatous craniopharyngioma, a brain tumor that can recur after treatment. You may be eligible if you’re within the age range and have measurable tumor on scan, with specific rules about prior therapy and recovery.
Washington D.C., District of ColumbiaAges 1–39 - NCT05286788RecruitingPhase 2
MEKTOVI for children with adamantinomatous craniopharyngioma
This Phase 2 trial tests MEKTOVI® to treat pediatric adamantinomatous craniopharyngioma (a type of brain tumor). It may help shrink or control the tumor after it has come back or grown again.
Washington D.C., District of ColumbiaAges 1–39 - NCT05303064RecruitingPhase 3
Study of weight gain medicine for teens with certain mood or psychosis
This Phase 3 study tests a treatment aimed at reducing unhealthy weight gain in teens with schizophrenia or bipolar I disorder, using changes in BMI (a height-and-weight measure). It may help families who are concerned about weight changes that can happen with some psychiatric medicines.
Washington D.C., District of ColumbiaAges 10–17 - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Washington D.C., District of ColumbiaAges 1–21 - NCT05658731Recruiting
Radiation planning study to protect thinking in children
This study compares how radiation is planned to see whether it better protects thinking and memory in children and young adults. It may help future patients by learning which planning approach leads to better cognitive (thinking) outcomes.
Washington D.C., District of ColumbiaAges 1–26 - NCT05674656RecruitingPhase 1/Phase 2
Testing dolutegravir and rilpivirine in HIV-positive children
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Washington D.C., District of ColumbiaAges 6–12 - NCT05734066RecruitingPhase 1/Phase 2
Lurbinectedin drug study for young people with Ewing sarcoma
This trial tests lurbinectedin, a cancer medicine, by itself (no other drugs) in children and young adults whose Ewing sarcoma has come back or did not respond to prior treatment. It aims to see how safe the drug is and whether it can help control the cancer.
Washington D.C., District of ColumbiaAges 2–30 - NCT05835310RecruitingPhase 3
IV anifrolumab for active lupus in children
This study tests whether an intravenous medicine called anifrolumab can safely improve active systemic lupus (SLE) in children. If you qualify, you may receive the study treatment and be closely monitored for safety and lupus symptoms.
Washington D.C., District of ColumbiaAges 5–17 - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Washington D.C., District of ColumbiaAges 1–39 - NCT06036199Recruiting
Focused ultrasound for movement problems in cerebral palsy
This trial tests if focused ultrasound can help reduce uncontrolled movements in children and young adults with cerebral palsy caused by a lack of oxygen at birth. It may offer an option for those whose current medications aren't working well enough.
Washington D.C., District of ColumbiaAges 8–22 - NCT06065228Recruiting
Tracking treatment progress in children with IBD
This study looks at a new way to measure how well treatment is working in children with inflammatory bowel disease (IBD). It uses a special eye test called pupillometry, which is painless and non-invasive, to see if it can help doctors adjust treatment earlier.
Washington D.C., District of ColumbiaAges 6–21 - NCT06193759RecruitingPhase 1
Immune cell therapy for malignant pediatric brain tumors
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
Washington D.C., District of ColumbiaAges 1–30
Pediatric ALL trials by city in District of Columbia
Where these studies are running in District of Columbia
Institutions with a site for the recruiting pediatric all studies listed above.
- Children's National Medical Center · 19 studies
- Sibley Memorial Hospital · 2 studies
- Alkermes Investigational Site
- GSK Investigational Site
- Local Institution - 0064
- MedStar Georgetown University Hospital
What taking part in a pediatric all study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Pediatric ALL trials in other states
Common questions
- Are there pediatric all clinical trials in District of Columbia?
- Yes. We're currently tracking 63 recruiting pediatric all studies with a site in District of Columbia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a pediatric all study in District of Columbia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in District of Columbia to take part?
- Not necessarily. These studies have a site in District of Columbia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a pediatric all trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New pediatric all studies open in District of Columbia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.